Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin plus Rituxan in relapsed or refractory follicular NHL
NCT00057343Phase 3Terminated
- Sponsor
- Biogen
- Start
- Mar 2003
- Countries
- 1
01
Overview
A Phase 3 trial of ibritumomab tiuxetan in follicular lymphoma (FL), sponsored by Biogen. Started Mar 2003; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00057343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00057343.